Patricia Van Arnum is Editorial Director at the Drug, Chemical & Associated Technologies Association (DCAT), where she is responsible for delivering informational services for DCAT members.
She is editor of DCAT Value Chain Insights, DCAT’s editorial newsletter providing news and analysis of the business of bio/pharmaceutical development and manufacturing covering the full spectrum of the bio/pharmaceutical manufacturing value chain. She also provides content advisement and support for DCAT’s volunteer committees.
Overall, she has more than 25 years of experience covering the Bio/Pharmaceutical, Fine-Chemical and Chemical industries as a business and science editor. She is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science and holds undergraduate degrees in chemistry, economics, and political science.
As we near the fourth quarter of 2022, what have been the key mergers and acquisitions thus far in the CDMO/CMO sector and what new CDMOs/CMOs have entered the market? DCAT Value Chain Insights takes a look.
How is current market volatility, led by inflationary pressures, supply-chain disruptions, and geopolitical uncertainty, impacting sourcing and supply decisions? A look at what is on the industry’s radar.
Feeling Pressure To Shorten Early Development Timelines?
Lengthy early-development timelines are common across new and emerging biotech companies for a multitude of reasons. Striking the right balance of speed, quality, risk, and investment allows you to shorten…
The European Commission proposed this week an emergency intervention in Europe’s energy markets to address recent dramatic price rises as the EU faces the effects of a severe mismatch between energy demand and supply. What is in the proposal?
What are the key issues and trends in play for the rest of 2022? From energy supply to inflationary pressures to new bio/pharmaceutical products launches, DCAT Value Chain Insights takes an inside look of what may be next.
Biomanufacturing on the Move: Which Companies Are Expanding?
A measure of innovation in the bio/pharma industry is to look at “first-in-class” new drug approvals, referring to drugs with new mechanisms of actions than existing therapies. A look at key trends, the companies, and products for first-in-class drugs.
Company Moves: The Latest in the Global Generics Market
Novartis’ decision to spin out Sandoz, its generics and biosimilars business, into a separate, stand-alone company is the latest move in the highly cost-competitive generics market. What was behind Novartis’ decision, and how does it fit with other recent deals?
How have the bio/pharmaceutical majors performed thus far in 2022? Which companies and products are on the upside, and which companies and products are not meeting expectations? An analysis of first-half 2022 results and key pipeline progress of the top companies.